Pharmacologic preconditioning with monophosphoryl lipid A is abolished by 5-hydroxydecanoate, a specific inhibitor of the K(ATP) channel

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 3, 1998, Pages 337-342

  Janin, Yves ^a   Qian, Yong Zhen ^a   Hoag, Jeffery B ^a   Elliott, Gary T ^b   Kukreja, Rakesh C ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ribi ImmunoChem Inc   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Endotoxin; Infarct size; Ischemia; K(ATP) channel; Preconditioning

Indexed keywords

DECANOIC ACID DERIVATIVE; PHOSPHORYL LIPID A; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ADENOSINE TRIPHOSPHATE; ANIMALS; DECANOIC ACIDS; HEMODYNAMIC PROCESSES; HYDROXY ACIDS; ISCHEMIC PRECONDITIONING; LIPID A; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POTASSIUM CHANNEL BLOCKERS; RABBITS;

EID: 0031704510     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199809000-00001     Document Type: Article

References (47)

1. Takayama K, Qureshi N, Ribi E, et al. Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis 1984;6:439-43.
2. Ulrich JR, Cantrell JL, Gustafson GL, et al. The adjuvant activity of monophosphoryl lipid A. In: Sprig DR, Koff WC, eds. Topics in vaccine adjuvant research. Boca Raton, FL: CRC Press, 1991:133-43.
3. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Response Mod 1984;3:1-9.
4. Madonna GS, Peterson JE, Ribi EE, et al. Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun 1986;52:6-11.
5. Myers KR, Beining P, Betts M, et al. Monophosphoryl lipid A behaves as a T-cell-independent type-1 carrier for hapten-specific antibody responses in mice. Infect Immun 1995;63:168-74.
6. Astiz ME, Rackow EC, Still JG, et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med 1995;23:9-17.
7. Nelson DW, Brown JM, Banerjee A, et al. Pretreatment with a non-toxic derivative of endotoxin induces functional protection against cardiac ischemia/reperfusion injury. Surgery 1991;110:365-9.
8. Brown JM, Grosso MA, Terada LS, et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A 1989;86:2516-20.
9. Elliott GT, Comerford ML, Smith JR, et al. Cardioprotective effect of monophosphoryl lipid A is mediated by opening of K-ATP channels in rabbit heart. J Am Coll Cardiol 1996;February 27:194A.
10. Zhao L, Kirsch CC, Hagen SR, et al. Preservation of global cardiac function in the rabbit following protracted ischemia/reperfusion using monophosphoryl lipid A (MLA). J Mol Cell Cardiol 1996; 28:197-208.
11. Yoshida K, Maaieh MM, Shipley JB, et al. Monophosphoryl lipid A induces pharmacologic "preconditioning" in rabbit hearts without expression of 70-kDa heat shock protein. Mol Cell Biochem 1996;156:1-8.
12. Yao Z, Auchampach JA, Pieper GM, et al. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovasc Res 1993;27:832-8.
13. + channels mediate the late preconditioning against myocardial infarction produced by monophosphoryl lipid A [Abstract]. Am J Physiol 1996;271:H2723-9.
14. McCullough JR, Normandin DE, Conder ML, et al. Specific blockade of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 1991;69:949-58.
15. 3H]glyburide, to neuronal and muscle preparations. J Pharmacol Exp Ther 1991;257:1162-71.
16. + channels by cromakalim and glyburide. Physiologist 1989;32:209.
17. + channel by 5-hydroxydecanoate in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1992;260:702-8.
18. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischaemic pre-conditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 1992;26:1054-62.
19. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effect of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993;72:1293-9.
20. Marber MS, Latchman DS, Walker JM, et al. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264-72.
21. ATP channels in memory associated with myocardial preconditioning. Drug News Perspect 1996;9:13-8.
22. Elliott GT, Comerford ML, Smith JR, et al. Myocardial ischemia/reperfusion protection using monophosphoryl lipid A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide. Cardiovasc Res 1996;32:1071-8.
23. Yoshida KI, Maaieh MM, Shipley JB, et al. Monophosphoryl lipid A induces pharmacologic "preconditioning" in rabbit hearts without concomitant expression of 70-kDa heat shock protein. Mol Cell Biochem 1996;159:73-80.
24. Baxter GF, Goodwin RW, Wright MJ, et al. Myocardial protection after monophosphoryl lipid A: studies of delayed anti-ischemic properties in rabbit heart. Br J Pharmacol 1996;117:1685-92.
25. Holaday DA, Smith FR. Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers. Anesthesiology 1981;54:100-6.
26. Siegfried MR, Ma XL, Lefer AM. Splanchnic vascular endothelial dysfunction in rat endotoxemia: role of superoxide radicals. Eur J Pharmacol 1992;212:171-6.
27. Zhou XB, Zhai XL, Ashtaf M. Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Circulation 1996;93:1177-84.
28. Meyer J, Traber DL. Nitric oxide and endotoxin shock. Cardiovasc Res 1992;26:558.
29. Knowles RG, Merrett M, Salter M, et al. Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochem J 1990;270:833-6.
30. Gray GA, Schott C, Julou-Schaeffer G, et al. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol 1991;103:1218-24.
31. Luas H, Watkins SC, Freeswick PD, et al. Characterization of inducible nitric oxide synthase expression in endotoxemic rat cardiac myocytes in vivo and following cytokine exposure in vitro. J Mol Cell Cardiol 1995;27:2015-29.
32. Shindo T, Ikeda U, Ohkawa F, et al. Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. Cardiovasc Res 1995;29:813-9.
33. McKenna TM, Li S, Tao S. PKC mediates LPS- and phorbol-induced cardiac cell nitric oxide synthase activity and hypocontractility. Am J Physiol 1995;269:H1891-8.
34. Song W, Furman BL, Parratt JR. Attenuation by dexamethasone of endotoxin protection against ischaemia-induced ventricular arrhythmias. Br J Pharmacol 1994;113:1083-4.
35. + channel of smooth muscle cells. FEBS Lett 1994;345:47-9.
36. + current in human and rabbit ventricular myocytes. Circ Res 1996;78:492-8.
37. Nichols CG, Ripoil C, Lederer WJ. ATP-sensitive potassium channel modulation of guinea pig ventricular action potential and contraction. Circ Res 1991;68:280-7.
38. Thornton J, Thornton CS, Sterling DL, et al. Blockade of ATP-sensitive potassium channels does not prevent preconditioning in the rabbit heart. Circ Res 1993;72:44-9.
39. Downey JM. An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning. Cardiovasc Res 1993;27:1565.
40. Gross GI, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992;70:223-33.
41. ATP channels in rat heart: blockade of ischemic and acetylcholine-mediated preconditioning by glibenclamide. Am J Physiol 1996;271:H23-8.
42. Grover GJ, McCullough DE, Conder DE, et al. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker. J Pharmacol Exp Ther 1989;16:98-104.
43. Grover GJ, Sleph PG, Dzwonczyk S. The pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthesized dogs. J Cardiovasc Res 1990;16:853-64.
44. + current in cardiac muscle. Proc Natl Acad Sci U S A 1988;85:8360-4.
45. + channel activators BRL 34915 and pinacidil in guinea pig cardiac muscle. Soc Neurosci Abstr 1988;14:945.
46. Winquist RJ, Heaney LA, Wallace AA, et al. Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J Pharmacol Exp Ther 1989;248:149-56.
47. Liu B, McCullough JR, Vassalle M. On the mechanism of increased potassium conductance by the potassium channel opener BRL 34915 in isolated ventricular myocytes. Drug Des Res 1990;19: 409-23.